Breast Cancer

Impasse over ‘chemo sparing’ tumour profiling tests for early breast cancer

Regulatory barriers mean that Australian women with breast cancer must pay $5000 to access ‘chemo sparing’  tumour profiling tests that are reimbursed as standard of care in other countries, a Parliamentary inquiry has been told. While tests such as Oncotype DX and MammaPrint are recommended and subsidised in many other developed countries, they have been ...

Already a member?

Login to keep reading.

© 2022 the limbic